Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $354 | $326 | $265 | $298 |
| % Growth | 8.8% | 23% | -11.1% | – |
| Cost of Goods Sold | $55 | $46 | $48 | $42 |
| Gross Profit | $299 | $279 | $216 | $256 |
| % Margin | 84.4% | 85.8% | 81.7% | 85.9% |
| R&D Expenses | $17 | $18 | $15 | $20 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $46 | $42 | $42 | $42 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $18 | $18 | $18 | $18 |
| Operating Expenses | $81 | $77 | $75 | $80 |
| Operating Income | $218 | $202 | $142 | $176 |
| % Margin | 61.5% | 62.2% | 53.4% | 58.9% |
| Other Income/Exp. Net | $1 | $2 | $2 | $3 |
| Pre-Tax Income | $219 | $205 | $144 | $178 |
| Tax Expense | $44 | $40 | $26 | $41 |
| Net Income | $175 | $165 | $118 | $137 |
| % Margin | 49.5% | 50.7% | 44.6% | 46% |
| EPS | 1.49 | 1.36 | 0.96 | 1.08 |
| % Growth | 9.6% | 41.7% | -11.1% | – |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 |
| Weighted Avg Shares Out | 117 | 121 | 123 | 126 |
| Weighted Avg Shares Out Dil | 122 | 124 | 127 | 129 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $4 | $5 | $5 |
| Depreciation & Amortization | $61 | $21 | $20 | $20 |
| EBITDA | $285 | $230 | $169 | $203 |
| % Margin | 80.3% | 70.6% | 63.7% | 68.2% |